Neurol. praxi. 2021;22(4):295-299 | DOI: 10.36290/neu.2021.061

Role of subcutaneous interferon beta-1a in treating relapsing-remitting multiple sclerosis

MUDr. Radek Ampapa

Neurologické oddělení Nemocnice Jihlava

In relapsing-remitting multiple sclerosis, the treatment with subcutaneous interferon β-1a (IFN β-1a) reduces the risk of clinical and radiological progression. Efficacy has been shown even in the stage of clinically isolated syndrome. Long-term data on the safety of IFN β-1a have been promising, including the treatment options during pregnancy and breast-feeding. Patient adherence to treatment with IFN β-1a is increased by the use of an electronic autoinjector. The ReMuS Registry has been collecting data on multiple sclerosis patients in the Czech Republic since 2013. An analysis of available data allows for a detailed characterization of patients treated with subcutaneous IFN β-1a. Information is available on the numbers of patients, their phenotype, pregnancy, capacity for work, or role of IFN β-1a in the treatment algorithm of multiple sclerosis.

Keywords: interferon β-1a, relapsing-remitting multiple sclerosis, ReMuS Registry.

Received: June 20, 2021; Revised: June 20, 2021; Accepted: August 19, 2021; Prepublished online: August 19, 2021; Published: September 1, 2021  Show citation